While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
Prior therapy with lenalidomide and shorter disease history were found to correlate with poorer outcomes.
The FDA has approved Sarclisa (isatuximab-irfc; Sanofi), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
For patients with newly diagnosed multiple myeloma, a less frequent dosing regimen of bortezomib may elicit a similar clinical response.
In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
For biologically effective dose ≤28 Gy10, small but significant increase seen in reirradiation rates
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
